Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) — which typically causes mild, cold-like symptoms in most adults but can be deadly for infants — during weeks 32-36 of pregnancy. New research suggests that vaccination earlier in that time-frame, closer to 32 weeks, could provide the best protection for newborns against RSV.